Quadra Logic Technologies Inc. deal

QLTIF signed a letter of intent with CIBA Vision Ophthalmics to develop QLTIF's light-activated Benzoporphyrin derivative (BPD) for ophthalmic indications. The collaboration initially will focus on de...